Published in Oncoimmunology on February 25, 2015
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res (2016) 0.86
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res (2015) 0.81
Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. Oncotarget (2017) 0.80
Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes. PLoS One (2016) 0.76
BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma. Oncoimmunology (2016) 0.76
Rationale for stimulator of interferon genes-targeted cancer immunotherapy. Eur J Cancer (2017) 0.75
Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics (2016) 0.75
Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer. Oncotarget (2016) 0.75
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. Transl Oncol (2017) 0.75
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology (2016) 0.75
Transcriptional and epigenetic regulation of T cell hyporesponsiveness. J Leukoc Biol (2017) 0.75
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells. Nat Commun (2017) 0.75
Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells. Oncoimmunology (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology (1968) 11.20
T cell exhaustion. Nat Immunol (2011) 11.08
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science (2003) 7.75
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
T cell anergy. Annu Rev Immunol (2001) 7.15
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Four faces of cellular senescence. J Cell Biol (2011) 6.86
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol (2000) 4.22
11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity. Nat Med (2001) 3.94
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 3.51
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood (2012) 3.02
Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol (2002) 3.01
Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 2.92
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization. J Exp Med (1984) 2.86
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
A family of serine esterases in lytic granules of cytolytic T lymphocytes. Cell (1987) 2.58
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest (2008) 2.52
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood (2002) 2.33
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol (2011) 2.10
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med (1983) 1.89
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Serine esterase in cytolytic T lymphocytes. Nature (1986) 1.85
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood (2009) 1.73
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol (2011) 1.69
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res (2003) 1.63
The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol (2013) 1.63
Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med (2014) 1.61
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest (2012) 1.57
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med (1985) 1.52
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer (2013) 1.50
Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res (2010) 1.39
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells. Front Immunol (2013) 1.34
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 1.33
Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor. J Cell Biol (1993) 1.29
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res (2011) 1.25
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Cancer Res (2013) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol (2002) 1.20
The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol (2003) 1.19
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol (2012) 1.14
Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res (2008) 1.13
Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res (2009) 1.06
Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology (2013) 1.03
Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med (2011) 1.02
Moving T memory stem cells to the clinic. Blood (2013) 1.02
Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? Trends Mol Med (2012) 1.01
Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol (1990) 0.98
Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci U S A (2006) 0.97
Antigen specific killing assay using CFSE labeled target cells. J Vis Exp (2010) 0.93
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med (2014) 0.93
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype. Cancer Immunol Immunother (2013) 0.88
CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol (2008) 0.87
Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int J Cancer (1990) 0.87
Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy. PLoS One (2014) 0.84
Retracted Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther (2012) 0.83
The CD8+ granzyme B+ T-cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells. Immunology (1998) 0.78